Skip to main content
SpringerLink
Log in

Introduction into Novel Constructs

  • Chapter
  • First Online:
Challenges in Protein Product Development

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 38))

  • 3567 Accesses

Abstract

New biologic molecules—such as mAb-derived formats, nanobodies, bispecifics, and fusion proteins —are quite diverse and come along with new formulation and process development challenges. The properties are very dependent on the molecule and difficult to generalize. Hence, only by selection of optimized formulation conditions it is ensured to keep challenging molecule properties under control. In addition, a variety of analytical methods needs to be applied to thoroughly investigate all critical quality attributes. Finally with regard to compatibility, appropriate experimental design that mimics clinical administration procedure is essential (including product in-use stability and stability during administration conditions) and creative solutions might be required to ensure clinical dosing. Thorough pharmaceutical development is key to enable integrity and stability of novel biologics compounds upon storage and administration .

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Elvin, et al. Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int. J. Pharm. 2013; 440(1, 2):83–98. http://www.sciencedirect.com/science/article/pii/S0378517311011690.

    Article  CAS  PubMed  Google Scholar 

  2. Carter PJ. Introduction to current and future protein therapeutics: A protein engineering perspective. Exp. Cell Res. 2011;317(9):1261–9.

    Article  CAS  PubMed  Google Scholar 

  3. Plitnick L, Herzyk D.. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Elsevier Science;2013.

    Chapter  Google Scholar 

  4. Wurch T, Pierré A, Depil S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol. 2012;30(11):575–582. http://www.sciencedirect.com/science/article/pii/S0167779912001163.

    Article  CAS  PubMed  Google Scholar 

  5. Gil D, Schrum AG. Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments. Adv. Biosci. Biotechnol. 2013;4:73–84. http://dx.doi.org/10.4236/abb.2013.44A011.

    Article  CAS  Google Scholar 

  6. Fast JL, Cordes AA, Carpenter JF, Randolph W, Physical Instability of a Therapeutic Fc Fusion Protein: domain contributions to conformational and colloidal stability. Biochemistry. 2009;48:11724–11736. http://pubs.acs.org/doi/pdf/10.1021/bi900853v.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kleemann GR, Beierle J, Nichols AC, Dillon TM, Pipes GD, Bondarenko PV. Characterization of IgG1 Immunoglobulins and Peptide-Fc Fusion Proteins by Limited Proteolysis in Conjunction with LC-MS. Anal. Chem. 2008;80:2001–2009. http://pubs.acs.org/doi/pdf/10.1021/ac701629v.

    Article  CAS  PubMed  Google Scholar 

  8. Chang B, Hershenson S. Practical approaches to protein formulation development. In: Carpenter J, Manning M, editors. Rational design of stable protein formulations. USA: Springer;2002. p. 1–25.

    Google Scholar 

  9. Gibson M. Pharmaceutical preformulation and formulation: a practical guide from candidate drug selection to commercial dosage form. CRC Press;2009.

    Google Scholar 

  10. Akers MJ. Excipient–drug interactions in parenteral formulations. J Pharmaceutical Sci. 2002;91(11):2283–2300.

    Article  CAS  PubMed  Google Scholar 

  11. Rathore N, Rajan RS, Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol. Progress. 2008;24(3):504–514.

    Article  CAS  PubMed  Google Scholar 

  12. Walsh G. Biopharmaceutical benchmarks 2014. Nat. Biotech. 2014;32(10):992–1000.

    Article  CAS  PubMed  Google Scholar 

  13. Harris RJ, Shire SJ, Winter C. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Develop. Res. 2004;61(3):137–154.

    Article  CAS  Google Scholar 

  14. Kiese S, Papppenberger A, Friess W, Mahler HC. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J. Pharm. Sci. 2008;97(10):4347–4366.

    Article  CAS  PubMed  Google Scholar 

  15. Ohtake S, Kita Y, Arakawa T. Interactions of formulation excipients with proteins in solution and in the dried state. Adv. Drug Delivery Rev. 2011;63(13):1053–1073.

    Article  CAS  PubMed  Google Scholar 

  16. Chang BS, Kendrick BS, Carpenter JF. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharmaceutical Sci. 1996;85(12):1325–1330.

    Article  CAS  PubMed  Google Scholar 

  17. Randolph T, Jones L. Surfactant-Protein Interactions. In: Carpenter J, Manning M. editors Rational design of stable protein formulations. USA: Springer;2002. p. 159–175.

    Google Scholar 

  18. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 1999;185(2):129–188.

    Article  CAS  PubMed  Google Scholar 

  19. Gad SC. Pharmaceutical manufacturing handbook: production and processes. Wiley;2008.

    Google Scholar 

  20. Rathore N, Rajan RS, Freund E. Impact of manufacturing processes on drug product stability and quality. In: Formulation and process development strategies for manufacturing biopharmaceuticals. Wiley;2010. p. 917–940.

    Chapter  Google Scholar 

  21. Patro SY, Freund E, Chang BS. Protein formulation and fill-finish operations. Biotechnol. Ann. Rev. Elsevier. 2002;8:55–84.

    Google Scholar 

  22. Kolhe P, Badkar A. Protein and solute distribution in drug substance containers during frozen storage and post-thawing: a tool to understand and define freezing–thawing parameters in biotechnology process development. Biotechnol. Progress 2011;27(2):494–504.

    Article  CAS  PubMed  Google Scholar 

  23. Thomas CR, Geer D. Effects of shear on proteins in solution. Biotechnol. Lett. 2011;33(3):443–456.

    Article  CAS  PubMed  Google Scholar 

  24. Lutz H. Rationally defined safety factors for filter sizing. J. Membrane Sci. 2009;341(1–2):268–278.

    Article  CAS  Google Scholar 

  25. Biddlecombe JG, Craig AV, Zhang H, Uddin S, Mulot S, Fish BC, Bracewell DG. Determining antibody stability: creation of solid-liquid interfacial effects within a high shear environment. Biotechnol. Prog. 2007;23(5):1218–22.

    PubMed  CAS  Google Scholar 

  26. Pikal M. Freeze-Drying of Proteins. Formulation and delivery of proteins and peptides. Am. Chem. Soc. 1994;567:120–133.

    Google Scholar 

  27. Newton DW. Drug incompatibility chemistry. Am. J. Health Syst. Pharm. 2009;66(4):348–357.

    Article  CAS  PubMed  Google Scholar 

  28. Gikic M, Di Paolo E, Pannatier A, Cotting J. Evaluation of physicochemical incompatibilities during parenteral drug administration in a paediatric intensive care unit. Pharmacy World Sci. 2000;22(3):88–91.

    Google Scholar 

  29. den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharmaceutical Res. 2011;28(4):920–933.

    Google Scholar 

  30. Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J. Immunotoxicology. 2014;11(2):99–109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Sreedhara A, Glover ZK, Piros N, Xiao N, Patel A, Kabakoff B. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J. Pharm. Sci. 2012;101(1):21–30.

    Article  CAS  PubMed  Google Scholar 

  32. Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J. Pharm. Sci. 2008;97(8):2924–2935.

    Article  CAS  PubMed  Google Scholar 

  33. ICH. Final guideline on Pharmaceutical Development Q8. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. I. I. C. o. Harmonization. 2008.

    Google Scholar 

  34. Bardin C A, Astier A, Vulto G, Sewell J, Vigneron R, Trittler M, Daouphars M, Paul M, Trojniak F, Pinguet P, French Society of Oncology. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. Ann Pharm Fr. 2011;69(4):221–31.

    Article  CAS  Google Scholar 

  35. Sharma M, Cheung J, Dabbara A, Petersen J. Intravenous admixture compatibility for sterile products: challenges and regulatory guidance. In: Kolhe P, Shah M, Rathore N, editors. Sterile product development. New York: Springer;2013. 6:461–474.

    Chapter  Google Scholar 

  36. Bye J, Platts L, Falconer R. Biopharmaceutical liquid formulation: a review of the science of protein stability and solubility in aqueous environments. Biotechnol. Lett. 2014;36(5):869–75.

    Article  CAS  PubMed  Google Scholar 

  37. Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. Protein–excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Delivery Rev. 2011;63(13):1118–1159.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biologics Process Research and Development, Early Phase Development, Pharmaceutical Development, Novartis Pharma AG, Basel, Switzerland

    Susanne Joerg & Margarida Rodrigues

  2. Biologics Process Research and Development, Integrated Biologics Profiling, Novartis Pharma AG, Basel, Switzerland

    Kapil Gupta

  3. Pharma and Biotech Drug Product Services, Lonza AG, Basel, Switzerland

    Susanne Joerg

Authors
  1. Susanne Joerg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kapil Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Margarida Rodrigues
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Joerg .

Editor information

Editors and Affiliations

  1. BioTherapeutics Research and Development Pharmaceutics Research and Development, Pfizer Inc., Andover, Massachusetts, USA

    Nicholas W. Warne

  2. Lonza AG, Drug Product Services, Basel, Basel Stadt, Switzerland

    Hanns-Christian Mahler

Rights and permissions

Reprints and permissions

Copyright information

© 2018 American Association of Pharmaceutical Scientists

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Joerg, S., Gupta, K., Rodrigues, M. (2018). Introduction into Novel Constructs. In: Warne, N., Mahler, HC. (eds) Challenges in Protein Product Development. AAPS Advances in the Pharmaceutical Sciences Series, vol 38. Springer, Cham. https://doi.org/10.1007/978-3-319-90603-4_22

Download citation

Publish with us

Policies and ethics

Search

Navigation